Research
Hormonal
Antidiabetic drugs like metformin and liraglutide exert part of their beneficial effects by modifying gut microbiota composition, specifically by increasing the abundance of Akkermansia muciniphila.
If you are taking metformin or liraglutide, part of their benefit may come from how they change your gut bacteria. This highlights the importance of gut health in diabetes management, even when using medication.
GoodSupportsHIGH confidence
several preclinical and clinical studies highlighted that metformin modifies the intestinal microbiota composition by inducing the growth of several bacteria, such as Akkermansia muciniphila... fecal transfer to germ-free mice improved glucose homeostasis in recipients of samples from patients who received metformin
Why this rating
Strong preclinical evidence (fecal transfer) and clinical observations.
Source
Impact of Gut Microbiota on Host Glycemic Control
Céline Gérard et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00029
narrative_reviewCited 210×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut microbiota composition directly influences host glycemic control and insulin sensitivity through mechanisms including incretin secretion, short-chain fatty acid (SCFA) production, and bile acid metabolism.Good
- Prebiotic supplementation with non-digestible carbohydrates (e.g., oligofructose, inulin) improves glucose tolerance and insulin response by increasing GLP-1 secretion and SCFA production.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →